Immunotherapeutic Strategy to Treat Recurrent Respiratory Papillomatosis


About this study

The purpose of this study is to develop a novel immunotherapeutic strategy to treat Recurrent Respiratory Papillomatosis (RRP) patients and cure the disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects 18  years of age or older,
  • Subjects who understand that participation is voluntary.
  • Subjects who are able to complete the informed consent process.

Exclusion Criteria:

  • Subjects who are younger than 18 years of age.
  • Subjects who had a current acute viral, bacterial, or fungal infection.
  • Subjects diagnosed with the Human Immunodeficiency Virus (HIV), or who have tested positive for HIV, documented by any licensed ELISA assay and confirmed by Western Blot procedures at any time prior to donation.
  • Pregnant women.

Eligibility last updated 8/30/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

SangKon Oh, Ph.D.

Open for enrollment

Contact information:

Alan Acuna Manriquez

(480) 342-2536

More information


Publications are currently not available

Mayo Clinic Footer